TY - JOUR T1 - Commentary on “The Risky Business of Studying Prognosis” JF - The Journal of Rheumatology JO - J Rheumatol SP - 1771 LP - 1771 DO - 10.3899/jrheum.130393 VL - 40 IS - 10 AU - ANNA BRODER AU - CHAIM PUTTERMAN Y1 - 2013/10/01 UR - http://www.jrheum.org/content/40/10/1771.1.abstract N2 - To the Editor:We have read with great interest the review1 of our recent article2. Lim and Feldman provide valuable insights into the multiple pitfalls and limitations of retrospective studies, aiming to guide readers in better understanding the methodological underpinnings of different study designs and to help in selecting optimal studies to inform their practice. We thank Lim and Feldman for their comments; we take this opportunity to clarify several points.First, we point out that our study does not meet the definition of a “prognostic study,” because “prognostic studies” imply a directional causal relationship between a predictor and an outcome. Indeed, Lim and Feldman quoted an … Address correspondence to Dr. Broder. E-mail: abroder{at}montefiore.org ER -